CRSP CRISPR Therapeutics AG

For the quarter ended 31/3/2023, CRISPR Therapeutics AG's revenues increased by 1,666,566.67% and amounted to 100.00M. Net income increased by 52.01% to -53.07M. Net assets decreased by NaN to N/A and EPS increased from -1.41 to -0.67.